Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis
Open accessAbstract
Obstructive lung disease is the major cause of morbidity and mortality in cystic fibrosis (CF). To identify risk factors contributing to FEV(1) decline in CF patients, we carried out a retrospective analysis of clinical and pulmonary function data in a population of CF patients followed up for 5 years and studied the correlation between clinical data and FEV(1) decline. Fifty-one adult CF patients were studied. The FEV(1) decline was related to the following clinical characteristics: CFTR genotype, age, gender, weight, height, age at diagnosis, baseline FEV(1), pancreatic function, presence of airway infection, pancreatic insufficiency and diabetes, number of exacerbations/year and intravenous (i.v.) antibiotic courses/year. Both the number of exacerbations/year and the number of i.v. antibiotic courses/year were strongly related to the FEV(1) decline. Patients with airway infection or with diabetes had significantly lower FEV(1) values during the study as compared with non-infected patients or patients without diabetes; however, both the presence of airway infection or diabetes did not affect the FEV(1) decline. These results suggest that the aggressive treatment of disease exacerbations is crucial for delaying lung function decline in CF.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pulmonary exacerbations are important clinical events associated with disease progression.
“Pulmonary exacerbations are important clinical events associated with disease progression21-24; elexacaftor–tezacaftor–ivacaftor resulted in a lower rate of pulmonary exacerbations, including severe events leading to hospitalization or treatment with intravenous antibiotics, than placebo.”
From Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele (2019) · cites this paper as [21]
Cited by
Sorted by citations
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198 · see citing works
Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis
de Boer, K., Vandemheen, K. L., Tullis, E., Doucette, S., Fergusson, D., Freitag, A., Paterson, N., Jackson, M., Lougheed, M. D., Kumar, V., et al. (2011) · Thorax · doi:10.1136/thx.2011.161117 · Cited by 271 · see citing works
Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations
Zemanick, E. T., Harris, J. K., Wagner, B. D., Robertson, C. E., Sagel, S. D., Stevens, M. J., Accurso, F. J., & Laguna, T. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062917 · Cited by 180 · see citing works
- Authors
- Amadori, A., Antonelli, A., Balteri, I., Schreiber, A., Bugiani, M., & De Rose, V.
- Affiliations
- Ospedale San Luigi Gonzaga (IT)
- ORCID
- Schreiber, Anja
- Venue
- Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 103
- Issue
- 3
- Pages
- 407-413
- ISSN
- 0954-6111 (ISSN-L)
- OpenAlex
- W2082031673
- Cited by
- 64
- References
- 0
- Citations by year
- 2023: 7 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 7 · 2016: 5 · 2015: 4 · 2014: 5 · 2013: 9 · 2012: 2
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Respiratory Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- cystic fibrosis, lung function decline, FEV1, pulmonary exacerbations, intravenous antibiotics, airway infection, CFTR genotype, pancreatic insufficiency, diabetes mellitus, risk factors, adult patients
- MeSH terms
- Adolescent, Adult, Anti-Bacterial Agents, Cystic Fibrosis, Female, Follow-Up Studies, Forced Expiratory Volume, Humans, Lung, Male, Middle Aged, Exocrine Pancreatic Insufficiency, Prognosis, Recurrence, Regression Analysis, Retrospective Studies, Disease Progression, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review